Avience Biomedicals Limited, originally incorporated as a private limited company in December 2019, transitioned to a public limited entity in September 2024. Headquartered in Noida, Uttar Pradesh, India, the company specializes in the manufacturing of In Vitro Diagnostic (IVD) products and medical devices. IVDs are crucial tools for detecting diseases, conditions, and infections, catering to critical diagnostic needs.
The company began by producing diagnostic kits such as Viral Transport Media (VTM) and tests for COVID-19, HIV, Malaria, Dengue, and HBs AG. Over time, Avience Biomedicals expanded its portfolio to include a wide range of medical devices, including serology products, biochemistry analyzers, and biochemistry reagents. These offerings are tailored for B2B and B2G markets, serving pathology labs, microbiology labs, hospitals, and research centers both domestically and internationally. The company also engages in the distribution and trading of medical equipment, reflecting its diversified capabilities.
In 2021, Avience Biomedicals established a new production facility in Noida to scale its operations and launched its e-commerce activities, enhancing market reach and operational efficiency. The company is now planning a fresh issue of 17,28,000 equity shares with a face value of Rs 10/- each, signaling its intentions for expansion and growth.
With its focus on affordable, high-quality healthcare solutions and its strong presence in both manufacturing and distribution, the company presents a compelling profile for traders eyeing opportunities in the medical consumable sector.